Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA4 | P22748 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18628115 | 0.94 | LPAR1 (0.37) | LPAR1LPAR2L3MBTL1CA12CA1 | |
| SCHEMBL3433166 | 0.90 | LPAR1 (0.31) | LPAR1LPAR2 | |
| SCHEMBL3434668 | 0.89 | LPAR1 (0.37) | LPAR1LPAR2L3MBTL1CA12CA1 | |
| SCHEMBL3433647 | 0.86 | L3MBTL1 (0.35) | L3MBTL1PPARD | |
| SCHEMBL3402232 | 0.82 | LPAR1 (0.39) | LPAR1LPAR2L3MBTL1CA12CA1 | |
| SCHEMBL15117017 | 0.72 | LTB4R (0.33) | LPAR1LPAR2PPARD | |
| SCHEMBL15423453 | 0.72 | KCNH2 (0.34) | PPARD | |
| SCHEMBL4598913 | 0.71 | P2RY6 (0.50) | — | |
| SCHEMBL8548578 | 0.71 | CTSA (0.45) | CTSA | |
| SCHEMBL9356167 | 0.70 | P2RY6 (0.44) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2052252-B1 | LUMINESCENT LANTHANIDE LABELLING REAGENTS AND THEIR USE | ABACUS DIAGNOSTICA OY (FI) | 2010-11-10 | — | — | EP | claimed |
| US-20100081211-A1 | LUMINESCENT LANTHANIDE LABELLING REAGENTS AND THEIR USE | ABACUS DIAGNOSTICA OY (FI) | 2010-04-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081211-A1 | LUMINESCENT LANTHANIDE LABELLING REAGENTS AND THEIR USE | SCLY, SRM, TST | LPAR1 3415/4885LPAR2 3306/4885L3MBTL1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.